The Scientist

» biobusiness

Most Recent

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.


image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 


image: 2014 Salary Survey Closed

2014 Salary Survey Closed

By | July 14, 2014

Check back for the results in November!


image: Banking on iPSCs

Banking on iPSCs

By | June 30, 2014

A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.


image: Agencies Partner to Help Commercialize Biomedical Discoveries

Agencies Partner to Help Commercialize Biomedical Discoveries

By | June 19, 2014

Collaborative effort from the US National Science Foundation and National Institutes of Health offers business training for federally funded researchers.


image: Guidelines for Gene Patent Ruling

Guidelines for Gene Patent Ruling

By | March 7, 2014

The USPTO offers guidance to its patent examiners on how to interpret the Supreme Court’s rulings in the recent Myriad and Prometheus cases.


image: Venter's New Venture

Venter's New Venture

By | March 5, 2014

The genomics pioneer is starting a new company that aims to tackle the mysteries of human aging.


image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

1 Comment

image: Geron’s Stem Cell Program Sold

Geron’s Stem Cell Program Sold

By | October 2, 2013

The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.


image: Biotech IPOs Surge

Biotech IPOs Surge

By | August 23, 2013

The drought has ended for biotech companies seeking to join the public market, but whether this upward swing will last is anybody’s guess.


Popular Now

  1. Antidepressant Exerts Epigenetic Changes
  2. Inside a Lab Mouse’s High-Fat Diet
  3. Remote Mind Control
  4. Image of the Day: Mother’s Love
Life Technologies